Research Analysts’ Recent Ratings Updates for Creative Medical Technology (CELZ)

Creative Medical Technology (NASDAQ: CELZ) recently received a number of ratings updates from brokerages and research firms:

  • 12/15/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/8/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/6/2025 – Creative Medical Technology was upgraded by analysts at Wall Street Zen to a “hold” rating.
  • 12/1/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/24/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/17/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/11/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/5/2025 – Creative Medical Technology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.

See Also

Receive News & Ratings for Creative Medical Technology Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.